RxDoctor Payments Data

Marcela Torres Gutierrez

Physician Assistant · Irving, TXNPI 1992315709

Payments from drug & device makers

$4,381in general payments, 2019–2025

Across 162 payments — averaging $27.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$869
  • Teleflex LLC$533
  • Johnson & Johnson$518
  • Astellas Pharma US Inc$427
  • Medtronic$365
  • Ferring Pharmaceuticals Inc.$255
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$942%
  • Food & beverage$3,99791%
  • Education$2897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,381 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$22,931
Medicare patients
160
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron171$108,018
GemtesaVibegron60$55,129
Mirabegron ErMirabegron14$6,888
Tamsulosin Hcl328$3,759
Finasteride207$2,782
Oxybutynin Chloride ErOxybutynin Chloride100$2,114
Methenamine Hippurate34$1,999
Estradiol22$1,302
Testosterone Cypionate24$1,130
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst81$1,125
Alfuzosin Hcl ErAlfuzosin Hcl24$769
Solifenacin Succinate17$681
Naproxen30$615
Ciprofloxacin Hcl56$443
Dutasteride16$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$427$108,018171 claims
Sumitomo Pharma America, Inc.Gemtesa$869$55,12960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →